- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03478670
Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Registry for Patients Treated With Strimvelis (Previously GSK2696273) Gene Therapy: Long-Term Prospective, Non-Interventional Follow-up of Safety and Effectiveness
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Lombardia
-
Milano, Lombardia, Italy, 20132
- Ospedale San Raffaele
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria
- Patient with ADA-SCID, treated with Strimvelis™ or GSK2696273, as part of its clinical development program.
- Adult patients, or patients for whom their parents or legal guardians have signed the informed consent form for participation in the registry.
There are no formal exclusion criteria for participation as this registry will follow all patients who have received Strimvelis™ prior to enrollment, subject to informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ADA-SCID subjects treated with Strimvelis
Subjects with ADA-SCID who have received Strimvelis (previously GSK2696273) gene therapy, comprising patients treated prior to marketing authorisation (i.e.
clinical studies and compassionate use programs) and those treated after marketing authorisation (including within compassionate use and early access programs).
|
Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only. This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intervention free survival
Time Frame: Up to 15 years
|
Intervention is defined as hematopoietic stem cell transplantation (HSCT) or >3 months of enzyme replacement therapy (ERT)
|
Up to 15 years
|
Number of subjects with the use of medications/treatments of interest
Time Frame: Up to 15 years
|
Subjects requiring ERT, HSCT, radiotherapy or cytotoxic agents will be assessed
|
Up to 15 years
|
Absolute peripheral lymphocyte for Immune reconstitution assessment
Time Frame: Up to 15 years
|
Peripheral lymphocyte will be assessed
|
Up to 15 years
|
Absolute cluster of differentiation (CD)3+ T-cell for Immune reconstitution assessment
Time Frame: Up to 15 years
|
CD3+ T-cell counts will be assessed
|
Up to 15 years
|
Absolute CD19+ B-cell counts for Immune reconstitution assessment
Time Frame: Up to 15 years
|
CD19+ B-cell counts will be assessed
|
Up to 15 years
|
Phytohaemagglutinin (PHA) and anti CD-3 as a measure for T cell function
Time Frame: Up to 15 years
|
Phytohaemagglutinin (PHA) and anti CD-3 will be assessed
|
Up to 15 years
|
Growth percentile in body height
Time Frame: Up to 15 years
|
Subject's height will be superimposed against gender specific World Health Organization (WHO) standard growth charts
|
Up to 15 years
|
Growth percentile in body weight
Time Frame: Up to 15 years
|
Subject's weight will be superimposed against gender specific WHO standard growth charts
|
Up to 15 years
|
Deoxyadenosine nucleotides (dAXP) levels in red blood cells for the measurement of systemic metabolite detoxification
Time Frame: Up to 15 years
|
Deoxyadenosine nucleotides (dAXP) levels will be assessed in red blood cells
|
Up to 15 years
|
Vector copy number measured in peripheral blood mononuclear cells (PBMCs)
Time Frame: Up to 15 years
|
Vector copy number will be measured
|
Up to 15 years
|
Number of subjects with severe infections
Time Frame: Up to 15 years
|
Severe infection is defined as an infection requiring hospitalization or prolonging hospitalization
|
Up to 15 years
|
Percentage of subjects with severe infections
Time Frame: Up to 15 years
|
Severe infection is defined as an infection requiring hospitalization or prolonging hospitalization
|
Up to 15 years
|
Length of hospital stay
Time Frame: Up to 15 years
|
Duration of the hospitalization will be monitored
|
Up to 15 years
|
Number of subjects with non-immunological manifestations of ADA SCID
Time Frame: Up to 15 years
|
Subjects will be examined for hepatic steatosis, cognitive deficits, behavioural abnormalities including suspected or diagnosed attention deficit hyperactivity disorder, autism, or hearing impairment
|
Up to 15 years
|
Pediatric development and quality of life data
Time Frame: Up to 15 years
|
Determination of attendance at school, if appropriate for age; whether the child is in an age appropriate grade/class at school; whether the child requires special educational support (example [e.g.] dedicated tutor); participation in sports as desired by child; requirement for hearing aid(s); adequate response to childhood vaccinations; severity of impact of a child's health on the guardian's intended employment and Karnofsky/Lansky performance status
|
Up to 15 years
|
Number of subjects with any adverse events (AEs) and any serious adverse events (SAEs) as a safety measure
Time Frame: Up to 15 years
|
AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement will be categorized as SAE
|
Up to 15 years
|
Number of subjects with abnormal clinical laboratory blood test results as a safety measure
Time Frame: Up to 15 years
|
Biochemistry, hematology and TSH parameters were assessed
|
Up to 15 years
|
Overall survival
Time Frame: After 15 years of follow-up, it will continue to be solicited every 2 years until the registry closes
|
Number and causes of death and time of onset of fatal events will be summarized.
Starting time will be the date of therapy administration.
|
After 15 years of follow-up, it will continue to be solicited every 2 years until the registry closes
|
Scores for Pediatric Quality of Life Questionnaire (Peds-QL)
Time Frame: Up to 15 years
|
Where they are used routinely as part of a physician's standard of care or where permitted by local authorities as non-interventional assessments.
The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population.
It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning.
Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL.
This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always).
Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored.
|
Up to 15 years
|
Scores for Ages and Stages Questionnaire-3[ASQ-3]
Time Frame: Up to 15 years
|
Where they are used routinely as part of a physician's standard of care or where permitted by local authorities as non-interventional assessments.
The ASQ-3 includes a series of questions designed to assess 5 areas of development: communication, gross motor, fine motor, problem solving, and personal social.
The questions target behaviours that are appropriate for particular developmental milestones.
|
Up to 15 years
|
Number of subjects with adverse events of interest
Time Frame: Up to 15 years (oncogenesis will continue to be solicited every 2 years until the registry closes)
|
AEs and SAEs related to medical or surgical procedures associated with Strimvelis™ administration (e.g.
central venous catheter, busulfan conditioning); oncogenesis, autoimmunity, unsuccessful response to gene therapy, hypersensitivity to the product, risks related to residuals present in the drug product administered to the patient, risks related to short shelf-life of product, non-immunologic manifestations of ADA-SCID (e.g.
hepatic steatosis, cognitive defects, behavioural abnormalities, hearing impairment), replication competent retrovirus.
|
Up to 15 years (oncogenesis will continue to be solicited every 2 years until the registry closes)
|
Number of subjects with fertility and pregnancy related outcomes
Time Frame: After 15 years of follow-up, it will continue to be solicited every 2 years until the registry closes
|
Labor and delivery information, full term pregnancy, caesarean section, abortion, miscarriage, ectopic, stillbirth rates will be assessed.
Both male and female fertility issues will be analyzed.
|
After 15 years of follow-up, it will continue to be solicited every 2 years until the registry closes
|
Data from Retroviral Insertion Site (RIS) analysis and replication competent retrovirus (RCR)
Time Frame: Up to 15 years
|
RIS and RCR will be performed when suspected malignancy or after a diagnosis of malignancy
|
Up to 15 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Fondazione Telethon, Fondazione Telethon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STRIM-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunologic Deficiency Syndromes
-
Yonsei UniversityCompletedImmune DeficiencyKorea, Republic of
-
Yonsei UniversityCompleted
-
University of Colorado, DenverColorado Clinical & Translational Sciences InstituteRecruiting
-
Johann Wolfgang Goethe University HospitalUnknownImmune DeficiencyGermany
-
Zealandina AgencyCompleted
-
University of VirginiaCSL Behring; Jeffrey Modell FoundationCompletedImmune DeficiencyUnited States
-
Université Catholique de LouvainTerminatedCombined Inflammatory and Immunologic DefectBelgium
-
Green Cross CorporationParexel; Atlantic Research GroupCompletedImmunologic Deficiency SyndromesCanada, United States
-
Assistance Publique - Hôpitaux de ParisUnknownImmune Deficiency and Early BMF in ChildhoodFrance
-
National Cancer Institute (NCI)CompletedLymphoma | Leukemia | Neoplasm | Immunologic Deficiency SyndromeUnited States
Clinical Trials on Strimvelis
-
Fondazione TelethonActive, not recruitingSevere Combined Immunodeficiency Due to ADA DeficiencyItaly
-
Fondazione TelethonCompletedSevere Combined Immunodeficiency Due to ADA DeficiencyItaly
-
Fondazione TelethonCompletedImmunologic Deficiency SyndromesItaly, Israel